Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma

Sarcomas are rare tumors with generally poor prognosis, for which current therapies have shown limited efficacy. Histone deacetylase inhibitors (HDACi) are emerging anti-tumor agents; however, little is known about their effect in sarcomas. By using established and patient-derived sarcoma cells with...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncogenesis
المؤلفون الرئيسيون: Di Martile, Marta, Desideri, Marianna, Tupone, Maria Grazia, Buglioni, Simonetta, Antoniani, Barbara, Mastroiorio, Carlotta, Falcioni, Rita, Ferraresi, Virginia, Baldini, Nicola, Biagini, Roberto, Milella, Michele, Trisciuoglio, Daniela, Del Bufalo, Donatella
التنسيق: Artigo
اللغة:Inglês
منشور في: Nature Publishing Group UK 2018
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833676/
https://ncbi.nlm.nih.gov/pubmed/29472530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0026-x
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة